Clinical Trial Update: Developing Oral LT3 Therapy for Heart Failure - HFrEF [Phase 1, Phase 2]

View source ↗

Summary

The University of Pennsylvania reports that Phase 1/2 trials of an oral LT3 therapy for heart failure with reduced ejection fraction (including Low T3 syndrome)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction
• Low T3 Syndrome

Drugs mentioned

• Oral LT3 therapy (triiodothyronine)

Snippet

Sponsor: University of Pennsylvania | Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF), Low T3 Syndrome | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-12-24